Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
Cancer Cell
; 40(6): 590-591, 2022 06 13.
Article
in En
| MEDLINE
| ID: mdl-35598602
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hematologic Neoplasms
/
COVID-19 Drug Treatment
Limits:
Humans
Language:
En
Journal:
Cancer Cell
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: